Ferring, Aventis Reach $20M Deal In DDAVP Antitrust Suit
By Abigail Rubenstein ( August 4, 2011, 3:50 PM EDT) -- Ferring BV and Aventis Pharmaceuticals Inc. on Wednesday agreed to pay $20.25 million to settle with a proposed class of direct purchasers of DDAVP who claimed in a New York suit that the companies suppressed generic competition by fraudulently acquiring a patent for the diabetes drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.